Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Promising preclinical study for DNAPrint candidate
As a result of the successful study in the animal model, DNAPrint has selected PT-502 as its lead compound for development. PT-502 uses the dopamine system in order
As a result of the successful study in the animal model, DNAPrint has selected PT-502 as its lead compound for development. PT-502 uses the dopamine system in order
In Celera’s research studies, two single nucleotide polymorphisms (SNPs) were identified in the DAPK1 (death-associated protein kinase 1) gene that showed significant association with late-onset Alzheimer’s disease. In
The milestone was related to progress in the preclinical development of MEM 63908, the second named development candidate in the company’s nicotinic alpha-7 agonist program. A number of
In December 2005, Wyeth and Progenics Pharmaceuticals entered into a collaboration agreement to develop and commercialize methylnaltrexone. The FDA fast track designation facilitates development and expedites regulatory review
The study, known as EVOLVE, is a clinical outcomes study designed to determine whether Sensipar (cinacalcet HCl), marketed as Mimpara in Europe, can effectively reduce the risk of
The 10-patient study, using a currently marketed drug of approximately 4,000 Daltons in size, revealed an average systemic bioavailability of approximately 35% for the Intravail formulation compared to
A total of 28 patients undergoing chronic haemodialysis were enrolled in an open-label multi-centre trial. Various doses were tested across a maximum of three dialysis sessions. All patients
The company said that the cause of death and the relationship of the study drug, known as DAC:GRF, to the event, which occurred at a clinical site in
According to the companies, the current lack of clinical methods for definitive diagnosis remains a significant impediment for the management of Alzheimer’s patients, as well as for the
Forest and its Danish partner H. Lundbeck won the case against Ivax Corp, a subsidiary of Teva, after it applied to the FDA for approval to sell a